Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 1999

View Archived Issues

Licensing opportunity from NIH: combination chemotherapy including a VIP antagonist

Available for licensing from NIH: gene therapy for chronic or persistent pain

Genta's BCL-2 antisense claims allowed in U.S.

Gemini Technologies awarded SBIR grant to study 2-5A antisense compound

Paradigm Genetics and Prionics to collaborate on diagnostic for BSE and CJD

ProdiGene patents edible vaccines

UBCLE: a new protein discovered at Incyte; antagonists useful for cancer, etc.

R&D highlights at Medco during Q2

Quinolone antibiotic-Mg2+ complexes have superior physicochemical/pharmacokinetic properties

P2X7 receptor antagonists for inflammatory, immune and cardiovascular disorders

Lanosterol synthase inhibitors under study at Boehringer Ingelheim

Guerbet's new contrast agents for MRI

Fungal metabolites useful as IL-1/TNF production inhibitors

Antiplatelet agents acting as IP receptor agonists developed at Fujisawa

Alza and Crescendo submit NDA for OROS methylphenidate

Phase II study results presented for Sibia's parkinsonian therapy

Extremely potent cytotoxic cryptophycin analogue discovered at Lilly

CDK2-inhibitory purine derivatives with potential in cancer therapy

New COX-2 inhibitor and celecoxib not effective in permanent MCAO model of focal cerebral ischemia

DP-B99: novel metal ion chelator proves effective in global and focal cerebral ischemia

Beneficial effects reported for new bradykinin B2 receptor antagonist in brain edema

News from BRAIN '99: role of MEK1/ERK pathway in ischemic brain injury

BRAIN '99: Daiichi presents results on clinical candidate for cerebral ischemia

New AMPA receptor antagonist from Boehringer Ingelheim shows promise as ischemic stroke Rx

First i.v. proton pump inhibitor under review by FDA

NeuroSearch describes 5-HT reuptake inhibitors fulfilling certain requirements for PET radiotracers

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026